Redx Pharma Strengthens Senior Team

Pioneering pharma company Redx has bolstered its senior team, appointing drug discovery expert Dr. Richard Armer as Chief Scientific Officer (CSO) and Phil Tottey FCCA as Chief Financial Officer (CFO).

Richard, who has worked for organisations including Pfizer, Organon and Oxagen, most recently held the role of CSO at Lectus Therapeutics. During his career, Richard has developed a particular focus on drug development activity. He specialises in drug disposition and intellectual property and has successfully identified positive leads for new drugs across a range of therapeutic areas. After joining Redx Oncology in early-2012 as Head of Chemistry, Richard moved to become Head of Research in December 2013.

Phil Tottey will bring significant financial and operational experience developed during a career spanning 34 years to his new role. He started his professional life with Grant Thornton in Liverpool, before developing a career which has spanned sectors including retail, construction and media. He is experienced working with both high-profile global organisations including media giant Emap, and local businesses, having successfully set up his own business offering training and consultancy to local SMEs in 2003. Phil joined Redx in 2013, initially as Financial Controller before becoming Group Operations Director in December that year.

Redx Pharma CEO, Dr Neil Murray said, “We’re delighted to make these appointments and further bolster our executive team. Phil and Richard both bring significant expertise and experience to the business and will continue to play an invaluable role in Redx’s ongoing growth and development.

“Richard’s remarkable technical expertise and scientific leadership has been of great value to Redx Oncology. As a pioneering business working at the frontline of drug development, applying those skills across the Redx group means that Richard will be a great asset to the team. “

Phil’s depth of experience across a range of sectors, coupled with his extensive capabilities are a formidable combination and we’re delighted to welcome him to his new position.”

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.